1. Key Insights 2. Hepatitis D Market Overview at a Glance 2.1. Market Share (%) Distribution of Hepatitis D in 2016 2.2. Market Share (%) Distribution of Hepatitis D in 2028 3. Disease Background and Overview: Hepatitis D 3.1. Introduction 3.2. Classification 3.3. Factors influencing Hepatitis D Progression 3.4. Disease Causes 3.5. HDV-Symptoms 3.6. Pathogenesis 3.7. Pathophysiology 3.8. HDV Diagnosis 3.9. Prevention 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. 8MM Prevalent Population of Hepatitis D 5. Country Wise-Epidemiology of Hepatitis D 5.1. United States 5.1.1. Prevalent cases of Hepatitis D in the United States 5.1.2. Prevalent Population of Hepatitis D by severity 5.1.3. Gender Specific Hepatitis D Prevalence 5.1.4. Age Specific Hepatitis D Prevalence 5.1.5. Diagnosed cases of Chronic Hepatitis D 5.2. EU5 5.2.1. Prevalent Population of Hepatitis D in EU5 5.3. France 5.3.1. Prevalent Population of Hepatitis D 5.3.2. Prevalent Population of Hepatitis D by severity 5.3.3. Gender Specific Hepatitis D Prevalence 5.3.4. Age Specific Hepatitis D Prevalence 5.3.5. Diagnosed cases of Chronic Hepatitis D 5.4. Germany 5.4.1. Prevalent Population of Hepatitis D 5.4.2. Prevalent Population of Hepatitis D by severity 5.4.3. Gender Specific Hepatitis D Prevalence 5.4.4. Age Specific Hepatitis D Prevalence 5.4.5. Diagnosed cases of Chronic Hepatitis D 5.5. Italy 5.5.1. Prevalent Population of Hepatitis D 5.5.2. Prevalent Population of Hepatitis D by severity 5.5.3. Gender Specific Hepatitis D Prevalence 5.5.4. Age Specific Hepatitis D Prevalence 5.5.5. Diagnosed cases of Chronic Hepatitis D 5.6. Spain 5.6.1. Prevalent Population of Hepatitis D 5.6.2. Prevalent Population of Hepatitis D by severity 5.6.3. Gender Specific Hepatitis D Prevalence 5.6.4. Age Specific Hepatitis D Prevalence 5.6.5. Diagnosed cases of Chronic Hepatitis D 5.7. United Kingdom 5.7.1. Prevalent Population of Hepatitis D 5.7.2. Prevalent Population of Hepatitis D by severity 5.7.3. Gender Specific Hepatitis D Prevalence 5.7.4. Age Specific Hepatitis D Prevalence 5.7.5. Diagnosed cases of Chronic Hepatitis D 5.8. Japan 5.8.1. Prevalent Population of Hepatitis D 5.8.2. Prevalent Population of Hepatitis D by severity 5.8.3. Gender Specific Hepatitis D Prevalence 5.8.4. Age Specific Hepatitis D Prevalence 5.8.5. Diagnosed cases of Chronic Hepatitis D 5.9. China 5.9.1. Prevalent Population of Hepatitis D 5.9.2. Prevalent Population of Hepatitis D by severity 5.9.3. Gender Specific Hepatitis D Prevalence 5.9.4. Age Specific Hepatitis D Prevalence 5.9.5. Diagnosed cases of Chronic Hepatitis D 6. Current Treatment Practices 7. Treatment Algorithm 8. Unmet needs 9. Emerging Therapies 9.1. Key Cross Competition 9.2. Phase II Drugs 9.3. Pegasys: Hoffmann-La Roche 9.3.1. Drug Description 9.3.2. Product Profile 9.3.3. Clinical Development 9.3.4. Clinical Trials Information 9.3.5. Safety and efficacy 9.3.6. Advantages and Disadvantages 9.4. REP 2139-Ca + Pegasys: Replicor Inc. 9.4.1. Drug Description 9.4.2. Product Profile 9.4.3. Other Development Activities 9.4.4. Clinical Development 9.4.5. Clinical Trials Information 9.4.6. Safety and Efficacy 9.4.7. Advantages and disadvantages 9.5. Myrcludex B: MYR Pharma 9.5.1. Drug Description 9.5.2. Product Profile 9.5.3. Other Development Activities 9.5.4. Clinical Development 9.5.5. Clinical Trials Information 9.5.6. Safety and efficacy 9.5.7. Advantages and disadvantages 9.6. Lonafarnib: Eiger BioPharmaceuticals 9.6.1. Drug Description 9.6.2. Product Profile 9.6.3. Regulatory milestones 9.6.4. Clinical Development 9.6.5. Clinical Trials Information 9.6.6. Safety and efficacy 9.6.7. Advantages and Disadvantages 9.7. Pegylated interferon lambda 1a: Eiger BioPharmaceuticals 9.7.1. Drug Description 9.7.2. Product Profile 9.7.3. Other development activities 9.7.4. Clinical Development 9.7.5. Clinical Trials Information 9.7.6. Safety and efficacy 9.7.7. Advantages and Disadvantages 10. Hepatitis D: Market Analysis 11. Key Findings 11.1. Hepatitis D: Total Market Size in 8MM 11.2. Total Market Size of Hepatitis D in 8MM 11.3. Therapy Based Market Size of Hepatitis D in 8MM 12. Market Size of Hepatitis D by Country 12.1. United States Market Analysis 12.1.1. Market Size of Hepatitis D in the US 12.1.2. Therapy Based Market Size of Hepatitis D in the US 12.2. Hepatitis D: EU5 Market Outlook 12.3. Germany 12.3.1. Market Size of Hepatitis D in Germany 12.3.2. Therapy Based Market Size of Hepatitis D in Germany 12.4. France 12.4.1. Market Size of Hepatitis D in France 12.4.2. Therapy Based Market Size of Hepatitis D in France 12.5. Italy 12.5.1. Market Size of Hepatitis D in Italy 12.5.2. Therapy Based Market Size of Hepatitis D in Italy 12.6. United Kingdom 12.6.1. Market Size of Hepatitis D in the UK 12.6.2. Therapy Based Market Size of Hepatitis D in the UK 12.7. Spain 12.7.1. Market Size of Hepatitis D in Spain 12.7.2. Therapy Based Market Size of Hepatitis D in Spain 12.8. Japan: Market Analysis 12.8.1. Market Size of Hepatitis D in Japan 12.8.2. Therapy Based Market Size of Hepatitis D in Japan 12.9. China: Market Analysis 12.9.1. Market Size of Hepatitis D in China 12.9.2. Therapy Based Market Size of Hepatitis D in China 13. Market Drivers of Hepatitis D 14. Market Barriers of Hepatitis D 15. Appendix 16. Report Methodology 16.1. Sources Used 17. DelveInsight Capabilities 18. Disclaimer 19. About DelveInsight

Table 1: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 2: The United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 3: The United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 4: The United States, Gender-Specific Hepatitis D Prevalence, 2016-2028 Table 5: The United States, Age-Specific Hepatitis D Prevalence, 2016-2028 Table 6: The United States, Diagnosed cases of Hepatitis D, 2016-2028 Table 7: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 8: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 9: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 10: France, Gender Specific Hepatitis D Prevalence, 2016-2028 Table 11: France, Age Specific Hepatitis D Prevalence, 2016-2028 Table 12: France, Diagnosed cases of Hepatitis D, 2016-2028 Table 13: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 14: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 15: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2028 Table 16: Germany, Age-Specific Hepatitis D Prevalence, 2016-2028 Table 17: Germany, Diagnosed cases of Hepatitis D, 2016-2028 Table 18: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 19: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 20: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2028 Table 21: Italy, Age-Specific Hepatitis D Prevalence, 2016-2028 Table 22: Italy, Diagnosed cases of Hepatitis D, 2016-2028 Table 23: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 24: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 25: Spain, Gender Specific Hepatitis D Prevalence, 2016-2028 Table 26: Spain, Age Specific Hepatitis D Prevalence, 2016-2028 Table 27: Spain, Diagnosed cases of Hepatitis D, 2016-2028 Table 28: The United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 29: The United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 30: The United Kingdom, Gender Specific Hepatitis D Prevalence, 2016-2028 Table 31: The United Kingdom, Age-Specific Hepatitis D Prevalence, 2016-2028 Table 32: The United Kingdom, Diagnosed cases of Hepatitis D, 2016-2028 Table 33: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 34: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 35: Japan, Gender Specific Hepatitis D Prevalence, 2016-2028 Table 36: Japan, Age Specific Hepatitis D Prevalence, 2016-2028 Table 37: Japan, Diagnosed cases of Hepatitis D, 2016-2028 Table 38: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Table 39: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Table 40: China, Gender Specific Hepatitis D Prevalence, 2016-2028 Table 41: China, Age Specific Hepatitis D Prevalence, 2016-2028 Table 42: China, Diagnosed cases of Hepatitis D, 2016-2028 Table 43: Phase I/II drug analysis Table 44: Pegasys, Clinical Trial Description, 2016 Table 45: REP 2139, Clinical Trial Description, 2016 Table 46: Myrcludex B, Clinical Trial Description, 2016 Table 47: Lonafarnib, Clinical Trial Description, 2016 Table 48: Lambda, Clinical Trial Description, 2016 Table 49: 8 Major Market Size of Hepatitis D in USD Million (2016-2028) Table 50: Therapy Based Market Size of Hepatitis D in 8MM in USD Million (2016-2028) Table 51: Market Size of Hepatitis D in the US, USD Million (2016-2028) Table 52: Therapy Based Market Size of Hepatitis D in the US in USD Million (2016-2028) Table 53: Market Size of Hepatitis D in Germany, USD Million (2016-2028) Table 54: Therapy Based Market Size of Hepatitis D in Germany in USD Million (2016-2028) Table 55: Market Size of Hepatitis D in France, USD Million (2016-2028) Table 56: Therapy Based Market Size of Hepatitis D in France in USD Million (2016-2028) Table 57: Market Size of Hepatitis D in Italy, USD Million (2016-2028) Table 58: Therapy Based Market Size of Hepatitis D in Italy in USD Million (2016-2028) Table 59: Market Size of Hepatitis D in the UK, USD Million (2016-2028) Table 60: Therapy Based Market Size of Hepatitis D in the UK in USD Million (2016-2028) Table 61: Market Size of Hepatitis D in Spain, USD Million (2016-2028) Table 62: Therapy Based Market Size of Hepatitis D in Spain in USD Million (2016-2028) Table 63: Market Size of Hepatitis D in Japan, USD Million (2016-2028) Table 64: Therapy Based Market Size of Hepatitis D in Japan in USD Million (2016-2028) Table 65: Market Size of Hepatitis D in China, USD Million (2016-2028) Table 66: Therapy Based Market Size of Hepatitis D in China in USD Million (2016-2028) Figure 1: Hepatitis Delta Virus Structure Figure 2: Pathogenesis of Hepatitis D Figure 3: Diagnostic markers in various hepatitis D disease patterns Figure 4: 8MM, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 5: The United States, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 6: The United States, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 7: The United States, Gender-Specific Hepatitis D Prevalence, 2016-2028 Figure 8: The United States, Age Specific Hepatitis D Prevalence, 2016-2028 Figure 9: The United States, Diagnosed cases of Hepatitis D, 2016-2028 Figure 10: EU5, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 11: France, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 12: France, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 13: France, Gender Specific Hepatitis D Prevalence, 2016-2028 Figure 14: France, Age-specific Hepatitis D Prevalence, 2016-2028 Figure 15: France, Diagnosed cases of Hepatitis D, 2016-2028 Figure 16: Germany, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 17: Germany, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 18: Germany, Gender-Specific Hepatitis D Prevalence, 2016-2028 Figure 19: Germany, Age-Specific Hepatitis D Prevalence, 2016-2028 Figure 20: Germany, Diagnosed cases of Hepatitis D, 2016-2028 Figure 21: Italy, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 22: Italy, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 23: Italy, Gender-Specific Hepatitis D Prevalence, 2016-2028 Figure 24: Italy, Age-Specific Hepatitis D Prevalence, 2016-2028 Figure 25: Italy, Diagnosed cases of Hepatitis D, 2016-2028 Figure 26: Spain, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 27: Spain, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 28: Spain, Gender Specific Hepatitis D Prevalence, 2016-2028 Figure 29: Spain, Age Specific Hepatitis D Prevalence, 2016-2028 Figure 30: Spain, Diagnosed cases of Hepatitis D, 2016-2028 Figure 31: The United Kingdom, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 32: The United Kingdom, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 33: The United Kingdom, Gender-Specific Hepatitis D Prevalence, 2016-2028 Figure 34: The United Kingdom, Age Specific Hepatitis D Prevalence, 2016-2028 Figure 35: The United Kingdom, Diagnosed cases of Hepatitis D, 2016-2028 Figure 36: Japan, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 37: Japan, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 38: Japan, Gender Specific Hepatitis D Prevalence, 2016-2028 Figure 39: Japan, Age Specific Hepatitis D Prevalence, 2016-2028 Figure 40: Japan, Diagnosed cases of Hepatitis D, 2016-2028 Figure 41: China, Historical & Forecasted Hepatitis D Prevalence, 2016-2028 Figure 42: China, Historical & Forecasted Prevalence of Hepatitis D by severity, 2016-2028 Figure 43: China, Gender Specific Hepatitis D Prevalence, 2016-2028 Figure 44: China, Age Specific Hepatitis D Prevalence, 2016-2028 Figure 45: China, Diagnosed cases of Hepatitis D, 2016-2028 Figure 46: Suggested Algorithm for Investigation and Treatment Figure 47: Diagnosis and Treatment of Hepatitis Delta Virus (HDV) infection Figure 48: Treatment algorithm Figure 49: Unmet Needs of HDV Figure 50: 8 Major Market Size of Hepatitis D in USD Million (2016-2028) Figure 51: Therapy Based Market Size of Hepatitis D in 8MM in USD Million (2016-2028) Figure 52: Market Size of Hepatitis D in the US, USD Million (2016-2028) Figure 53: Therapy Based Market Size of Hepatitis D in the US in USD Million (2016-2028) Figure 54: Market Size of Hepatitis D in Germany, USD Million (2016-2028) Figure 55: Therapy Based Market Size of Hepatitis D in Germany in USD Million (2016-2028) Figure 56: Market Size of Hepatitis D in France, USD Million (2016-2028) Figure 57: Therapy Based Market Size of Hepatitis D in France in USD Million (2016-2028) Figure 58: Market Size of Hepatitis D in Italy, USD Million (2016-2028) Figure 59: Therapy Based Market Size of Hepatitis D in Italy in USD Million (2016-2028) Figure 60: Market Size of Hepatitis D in the UK, USD Million (2016-2028) Figure 61: Therapy Based Market Size of Hepatitis D in The UK in USD Million (2016-2028) Figure 62: Market Size of Hepatitis D in Spain, USD Million (2016-2028) Figure 63: Therapy Based Market Size of Hepatitis D in Spain in USD Million (2016-2028) Figure 64: Market Size of Hepatitis D in Japan, USD Million (2016-2028) Figure 65: Therapy Based Market Size of Hepatitis D in Japan in USD Million (2016-2028) Figure 66: Market Size of Hepatitis D in China, USD Million (2016-2028) Figure 67: Therapy Based Market Size of Hepatitis D in China in USD Million (2016-2028) Figure 68: Market Drivers of HDV Figure 69: Market Barriers of HDV